According to the Global Burden of Disease (GBD), it was considered the 3rd most common cause of disability, and the 2nd most common cause of mortality after ischemic heart diseases [1] For years, the lines of stroke management were limited only to rehabilitation and secondary prevention until the approval of recombinant tissue plasminogen activator (rt-PA) as a thrombolytic therapy for stroke by FDA at 1996 [2]. The gene discussed is PLAT; the disease is stroke disorder.